Theriva Biologics, Inc. (TOVX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Theriva Biologics reported revenue of $0. Net income was -$23.7M, or -$2.08 per diluted share. Operating activities generated -$16.7M of cash, leaving -$16.7M of free cash flow. At fiscal year end, Theriva Biologics held $38.2M in total assets against $22.9M in total liabilities, including $13.1M of cash and equivalents.
Open the full interactive Theriva Biologics financials → Quarterly statements, key ratios, valuation history and price charts.
Theriva Biologics Key Stats
| Share Price | $0.22 |
|---|---|
| Market Cap | $10.1M |
| 52-Week Range | $0.18 – $0.84 |
| Shares Outstanding | 45.9 million (basic, 2026 Q2) |
Theriva Biologics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$10.2M | -$14.3M | -$21.6M | -$21.4M | -$26.3M | -$24.1M |
| Pre-Tax Income | -$10.0M | -$14.3M | -$21.1M | -$20.0M | -$25.7M | -$23.7M |
| Income Tax | $0 | $0 | -$1.4M | -$1.6M | $0 | -$39,000 |
| Net Income | -$10.0M | -$14.3M | -$19.7M | -$18.3M | -$25.7M | -$23.7M |
| Diluted EPS | -$165.00 | -$47.50 | -$32.75 | -$28.50 | -$19.03 | -$2.08 |
Theriva Biologics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $300,000 | $0 |
| Net Income | -$4.4M | -$2.0M | -$2.0M | -$3.2M |
| Diluted EPS | -$0.45 | -$0.16 | -$0.05 | -$0.07 |
Theriva Biologics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.2M | $67.3M | $41.8M | $23.2M | $11.6M | $13.1M |
| Current Assets | $7.9M | $68.9M | $45.5M | $27.4M | $16.3M | $17.5M |
| Total Assets | $8.4M | $70.4M | $71.9M | $55.2M | $35.4M | $38.2M |
| Current Liabilities | $3.0M | $3.6M | $7.1M | $6.7M | $7.6M | $10.0M |
| Total Long-Term Debt | — | — | $221,000 | $162,000 | $92,000 | $1.7M |
| Total Liabilities | $3.2M | $5.0M | $17.3M | $15.5M | $16.3M | $22.9M |
| Shareholders' Equity | -$4.8M | $65.4M | $51.8M | $37.0M | $19.1M | $15.4M |
Theriva Biologics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.2M | -$12.9M | -$19.1M | -$19.0M | -$16.9M | -$16.7M |
| Cash From Investing | -$9,000 | -$14,000 | -$4.4M | -$202,000 | -$1,000 | -$35,000 |
| Cash From Financing | $3.4M | $74.0M | -$1.9M | $625,000 | $5.5M | $18.2M |
| Free Cash Flow | -$12.2M | -$12.9M | -$19.2M | -$19.2M | -$16.9M | -$16.7M |
Figures from Theriva Biologics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Theriva Biologics financials page for every line item.
Theriva Biologics Company Profile
| Ticker | TOVX |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Rockville, Maryland |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000894158 |
Frequently Asked Questions
What was Theriva Biologics' revenue in fiscal 2025?
Theriva Biologics (TOVX) reported revenue of $0 for fiscal 2025.
What is Theriva Biologics' annual revenue history?
Theriva Biologics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Theriva Biologics' net income in fiscal 2025?
Theriva Biologics reported net income of -$23.7M for fiscal 2025.
What was Theriva Biologics' earnings per share (EPS) in fiscal 2025?
Theriva Biologics' diluted EPS was -$2.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Theriva Biologics generate in fiscal 2025?
Theriva Biologics generated -$16.7M of free cash flow in fiscal 2025.
What was Theriva Biologics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Theriva Biologics reported revenue of $0.
How much debt does Theriva Biologics have?
Theriva Biologics reported $1.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Theriva Biologics are outstanding?
Theriva Biologics reported a weighted average of 45.9 million basic shares outstanding in 2026 Q2.
What is Theriva Biologics' market cap?
Based on its latest closing price, Theriva Biologics (TOVX) has a market capitalization of about $10.1M.
When does Theriva Biologics' fiscal year end?
Theriva Biologics' fiscal year end, as registered with the SEC, is December 31.
Where is Theriva Biologics headquartered?
Theriva Biologics lists its business address in Rockville, Maryland in its SEC filings.